Emeritus Professor Graham Russell
PhD, DM(Oxon), MD, FRCP, FRCPath. FMedSci, FRS
School of Medicine and Population Health
Emeritus Professor of Musculoskeletal Pharmacology


+44 7768 502842
Full contact details
School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
Graham Russell (R G G Russell) graduated with First Class Honours in Biochemistry from the University of Cambridge in 1962 and subsequently gained his PhD on pyrophosphate metabolism from the MRC Mineral Metabolism Unit at the University of Leeds. In 1965, he joined Dr Herbert Fleisch’s Medical Research Institute in Davos, Switzerland, and their collaborative work led to the discovery of the biological effects of bisphosphonates. He then moved to Oxford University, where he continued research based at the Nuffield Department of Orthopaedic Surgery. Working with Roger Smith, this led to the first and successful clinical applications of bisphosphonates in Paget’s disease of bone. Concurrently, he completed his medical degree with distinction in 1971. He held the Medical Research Fellowship at St Peter’s College from 1972-76. He was awarded his DM at Oxford in 1976, and also gained Membership and then the Fellowship of the Royal Colleges of Physicians and of Pathology.
During the 1970s, he held appointments in the University of Berne with Herbert Fleisch, and at Harvard University with John Potts and Stephen Krane as the Chiefs of the Endocrine and Arthritis Units respectively at the Massachusetts General Hospital, before moving in 1976 to the Department of Chemical Pathology in the University of Sheffield Medical School, under the leadership of Jack Martin. He became Professor and Head of Department of Human Metabolism and Clinical Biochemistry in 1977. Over the following years he helped to establish Sheffield as a major international centre for the study of basic and clinical aspects of bone diseases, and his group have nurtured many clinicians and PhDs who now hold senior positions in the field.
He has worked on topics related to calcium metabolism and bone diseases throughout his career and is author of more than 500 publications. He has played a central role in studying the biological effects of bisphosphonates, and in their clinical development and evaluation for the treatment of bone disorders, which includes Paget’s disease, myeloma, cancer metastases in bone, and osteoporosis. The use of bisphosphonates has now grown to a multi-billion dollar activity by the pharmaceutical industry. During the 1990s, Michael Rogers and others within his group in Sheffield elucidated the molecular mechanisms of action of the bisphosphonates, and showed that nitrogen-containing bisphosphonates act as inhibitors of mevalonate metabolism resulting in inhibition of protein prenylation. His research interests have included bone cell biology, pathogenic mechanisms in bone and joint diseases such as arthritis, myeloma, bone metastases, and osteoporosis, the evaluation of new therapeutic agents and their mode of action, and the pharmacology of bone and cartilage.
He has held several national and international appointments in scientific and charitable activities related to bone disease and arthritis. For the Nuffield Foundation (UK), he was Chairman of the Oliver Bird Committee from 1996-2003. He has been Chairman of the Scientific Advisory Committee of the National Association for Pagets Disease (UK), and of several Research Committees including the MRC, Research into Ageing, and the Arthritis Research UK (formerly ARC). In April 1997 he was Chairman of the 25th European Symposium for Calcified Tissues held in Harrogate, UK. From 1998-2001 he was the President of the International Bone and Mineral Society (IBMS), the longest established international academic society in this field. In 1986 he was one of the founding members of the National Osteoporosis Society (NOS, UK), which has grown to become one of the largest national charities devoted to osteoporosis, and from 2000-2002 he was Chairman of its Council of Management.
Among awards, he was Heberden Orator of the BSR in 1993, and was recipient of the John B. Johnson award of the Paget’s Foundation (USA) in 1997, and the Kohn award of the NOS in 2000. He received the W F Neuman award of the American Society of Bone and Mineral Metabolism in 2000. This is the most senior award of the ASBMR and he was the first British scientist to receive it. In 2007 he received the Pieter Gaillard Founders award of the IBMS, and in 2008 was elected a Fellow of the Royal Society of London.
In 2001 he moved back to the University of Oxford as the holder of the newly established Norman Collisson Chair of Musculoskeletal Sciences, and became a Professorial Fellow at St Peter’s College. From 2003-6 he was Head of the Nuffield Department of Orthopaedic Surgery (now NDORMS). He was the first Director of the Oxford University Institute of Musculoskeletal Sciences (the Botnar Research Centre), from 2002-7. He is now Professor of Musculoskeletal Pharmacology and continues his research within the Botnar Research Centre, and also in the Mellanby Centre for Bone Research at Sheffield University.
- Research interests
-
Graham’s research interests include bone cell biology, cytokines, pathogenic mechanisms in bone and joint diseases such as arthritis, myeloma, bone metastases, and osteoporosis, and the evaluation of new therapeutic agents and their modes of action.
Throughout he has played a central role in studying the biological effects of bisphosphonates, and in their clinical development and evaluation for the treatment of skeletal diseases. During the 1990s, Michael Rogers and others within his group in Sheffield elucidated the molecular mechanisms of action of the bisphosphonates, and showed that nitrogen-containing bisphosphonates act as inhibitors of mevalonate metabolism resulting in inhibition of protein prenylation. His current research focuses on understanding their structure activity relationships, the design of novel compounds, and the detailed mechanisms of their actions on the skeleton and other systems.
- Publications
-
Show: Featured publications All publications
Featured publications
This person does not have any publications available.
All publications
Books
- Foreword I. Elsevier.
Journal articles
- Rapid assessment of the osteogenic capacity of hydroxyapatite/aragonite using a murine tibial periosteal ossification model. Bioactive Materials, 45, 257-273.
- In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers. Aging, 15(9), 3331-3355.
- Introduction to the Bisphosphonate Special Issue. Bone, 172, 116754-116754.
- Real-time impedance-based monitoring of the growth and inhibition of osteomyelitis biofilm pathogen Staphylococcus aureus treated with novel bisphosphonate-fluoroquinolone antimicrobial conjugates. International Journal of Molecular Sciences, 24(3).
- Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone, 156, 116289-116289.
- Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 17(1).
- Bisphosphonates in dentistry: Historical perspectives, adverse effects, and novel applications. Bone, 147, 115933-115933.
- Bisphosphonates for delivering drugs to bone. British Journal of Pharmacology, 178(9), 2008-2025.
- Advances in the molecular pharmacology of bone and cancer‐related bone diseases. British Journal of Pharmacology, 178(9), 1889-1890.
- Zoledronate. Bone, 137, 115390-115390.
- History of alendronate. Bone, 137, 115411-115411.
- Differences in intracellular localisation of ANKH mutants that relate to mechanisms of calcium pyrophosphate deposition disease and craniometaphyseal dysplasia. Scientific Reports, 10(1).
- Clinical Guidelines on Paget's Disease of Bone. Journal of Bone and Mineral Research, 34(12), 2327-2329.
- Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to preventSQSTM1-mediated Paget’s disease of bone. BMJ Open, 9(9), e030689-e030689. View this article in WRRO
- Drugs for the treatment of metabolic bone diseases. British Journal of Clinical Pharmacology, 85(6), 1049-1051.
- Pharmacology of bisphosphonates. British Journal of Clinical Pharmacology, 85(6), 1052-1062.
- Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. Journal of Bone and Mineral Research, 34(4), e3657-e3657.
- Abstracts from the First Scientific Meeting of the Soft Bones Foundation. JBMR Plus, 2(S2), S1-S14.
- Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types. Journal of Bone and Mineral Research, 33(12), 2091-2098.
- The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1‐Fluoro‐2‐(Imidazo‐[1,2‐α]Pyridin‐3‐yl)‐Ethyl‐Bisphosphonate). Journal of Bone and Mineral Research, 32(9), 1860-1869. View this article in WRRO
- GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates. New England Journal of Medicine, 376(18), 1794-1795.
- Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms. Journal of Medicinal Chemistry, 60(6), 2326-2343. View this article in WRRO
- Ignac Fogelman: 1948–2016. Journal of Bone and Mineral Research, 31(10), 1785-1786.
- Pyrophosphate: a key inhibitor of mineralisation. Current Opinion in Pharmacology, 28, 57-68.
- Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. STEM CELLS, 34(3), 756-767. View this article in WRRO
- Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine. Bioconjugate Chemistry, 27(2), 329-340.
- Developments in the synthesis of new functionalized bisphosphonate drug candidates such as cyclic prodrugs. Phosphorus, Sulfur, and Silicon and the Related Elements, 191(11-12), 1504-1508.
- The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. Bone, 81, 478-486.
- Pharmacological diversity among drugs that inhibit bone resorption. Current Opinion in Pharmacology, 22, 115-130.
- Editorial overview: Musculoskeletal: Are there common targets to prevent age-related changes in muscle, cartilage and bone?. Current Opinion in Pharmacology, 22, v-viii.
- Tribute To Stephen M Krane. Journal of Bone and Mineral Research, 30(5), 751-752.
- Professor Christopher Nordin: in memoriam. Urolithiasis, 43(1), 1-2.
- Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted. BMJ, 346(mar12 3), f1514-f1514.
- Bisphosphonates and colon cancer: reply. Osteoporosis International, 24(3), 1141-1142.
- Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study. Osteoporosis International, 23(11), 2693-2701.
- Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. Journal of Bone and Mineral Research, 27(4), 835-847.
- Esophageal and gastric cancer incidence and mortality in alendronate users. Journal of Bone and Mineral Research, 27(3), 679-686.
- Bisphosphonate Binding Affinity Affects Drug Distribution in Both Intracortical and Trabecular Bone of Rabbits. Calcified Tissue International, 90(3), 202-210.
- Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporosis International, 23(1), 285-294.
- Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporosis International, 23(12), 2873-2884.
- Potential therapeutic effects of oral bisphosphonates on the intestine. Annals of the New York Academy of Sciences, 1240(1), E19-E25.
- Foreword: Bisphosphonates. Bone, 49(1), 1-1.
- Bisphosphonates: The first 40years. Bone, 49(1), 2-19.
- Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone, 48(4), 677-692.
- Atrial fibrillation and the use of oral bisphosphonates. Therapeutics and Clinical Risk Management, 7, 131-144. View this article in WRRO
- Molecular Characterization of a Novel Geranylgeranyl Pyrophosphate Synthase from Plasmodium Parasites. Journal of Biological Chemistry, 286(5), 3315-3322.
- Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone, 49(1), 133-139.
- The relationship between the chemistry and biological activity of the bisphosphonates. Bone, 49(1), 20-33.
- From Nuclear Physics to bone cell biology – Maureen Owen – 1927–2011. Bone, 49(6), 1121-1124.
- 2009 Santa Fe Bone Symposium. Journal of Clinical Densitometry, 13(1), 1-9.
- Differences between bisphosphonates in binding affinities for hydroxyapatite. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 92B(1), 149-155.
- Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres. Journal of Biomedical Materials Research Part A, 9999A, NA-NA.
- Targeting a Uniquely Nonspecific Prenyl Synthase with Bisphosphonates to Combat Cryptosporidiosis. Chemistry & Biology, 15(12), 1296-1306.
- Fluorescently Labeled Risedronate and Related Analogues: “Magic Linker” Synthesis. Bioconjugate Chemistry, 19(12), 2308-2310.
- Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolutionin vitro. Journal of Biomedical Materials Research Part A, 85A(4), 993-1000.
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International, 19(6), 733-759.
- Regulation of bim in glucocorticoid-mediated osteoblast apoptosis. Journal of Cellular Physiology, 215(2), 488-496.
- Structure–Activity Relationships Among the Nitrogen Containing Bisphosphonates in Clinical Use and Other Analogues: Time-Dependent Inhibition of Human Farnesyl Pyrophosphate Synthase. Journal of Medicinal Chemistry, 51(7), 2187-2195.
- Synthesis and Biological Evaluation of α-Halogenated Bisphosphonate and Phosphonocarboxylate Analogues of Risedronate. Journal of Medicinal Chemistry, 50(24), 5967-5975.
- Herbert Andre Fleisch, MD. Osteoporosis International, 18(8), 1019-1021.
- Apomine Enhances the Antitumor Effects of Lovastatin on Myeloma Cells by Down-Regulating 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase. Journal of Pharmacology and Experimental Therapeutics, 322(1), 228-235.
- Determinants of structure–function relationships among bisphosphonates. Bone, 40(5), S21-S25.
- Apomine™, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. International Journal of Cancer, 120(8), 1657-1663.
- Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia, 21(4), 805-812.
- Serum from Postmenopausal Women Directs Differentiation of Human Clonal Osteoprogenitor Cells from an Osteoblastic toward an Adipocytic Phenotype. Calcified Tissue International, 80(4), 233-243.
- Bespoke Human Hypertrophic Chondrocytic Cell Lines Provide the Osteoinductive Signals Required for Vascularized Bone Formation. Tissue Engineering, 13(1), 133-145.
- Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. International Journal of Cancer, 119(6), 1254-1261.
- The Crystal Structure of Human Geranylgeranyl Pyrophosphate Synthase Reveals a Novel Hexameric Arrangement and Inhibitory Product Binding. Journal of Biological Chemistry, 281(31), 22004-22012.
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proceedings of the National Academy of Sciences, 103(20), 7829-7834.
- Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone, 38(5), 617-627.
- Ibandronate: Pharmacology and preclinical studies. Bone, 38(4), S7-S12.
- Association of sporadic chondrocalcinosis with a ?4-basepair G-to-A transition in the 5?-untranslated region ofANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis & Rheumatism, 52(4), 1110-1117.
- Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporosis International, 15(6).
- Genetic studies of disorders of calcium crystal deposition. Rheumatology, 41(7), 725-729.
- Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?. QJM, 94(11), 575-597.
- Statins and Bone: Myth or Reality?. Calcified Tissue International, 69(2), 63-66.
- MDC-9 (ADAM-9/Meltrin γ) Functions as an Adhesion Molecule by Binding the αvβ5 Integrin. Biochemical and Biophysical Research Communications, 280(2), 574-580.
- Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98(13), 3534-3540.
- Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone, 28(1), 108-112.
- Extracellular ATP and UTP stimulate cartilage proteoglycan and collagen accumulation in bovine articular chondrocyte pellet cultures. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1502(2), 297-306.
- The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. British Journal of Haematology, 111(1), 283-286.
- Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. British Journal of Haematology, 108(2), 383-390.
- Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. The Lancet, 355(9200), 265-269.
- Bisphosphonates - Mechanisms of Action in Multiple Myeloma. Acta Oncologica, 39(7), 829-835.
- Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International, 11(4), 331-337.
- The Bisphosphonate Odyssey. A Journey from Chemistry to the Clinic. Phosphorus, Sulfur, and Silicon and the Related Elements, 144(1), 793-820.
- The pharmacology of bisphosphonates and new insights into their mechanisms of action. Journal of Bone and Mineral Research, 14(S2), 53-65.
- Regulation of Osteogenic Differentiation of Human Bone Marrow Stromal Cells: Interaction Between Transforming Growth Factor-β and 1,25(OH) 2 Vitamin D 3 In Vitro. Calcified Tissue International, 65(2), 173-180.
- Cloning of a fragment of the osteonectin gene from goldfish, Carassius auratus: Its expression and potential regulation by estrogen. General and Comparative Endocrinology, 114(1), 80-87. View this article in WRRO
- Divergent regulation of 1,25-dihydroxyvitamin D3 on human bone marrow osteoclastogenesis and myelopoiesis. Journal of Cellular Biochemistry, 72(3), 387-395.
- Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma. British Journal of Haematology, 104(2), 350-357.
- Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proceedings of the National Academy of Sciences, 96(1), 133-138.
- Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses. Osteoporosis International, 9(S2), S66-S80.
- Bisphosphonates: from the laboratory to the clinic and back again. Bone, 25(1), 97-106.
- Molecular mechanisms of action of bisphosphonates. Bone, 24(5), 73S-79S.
- Anti-Tumour Activity of Bisphosphonates in Human Myeloma Cells. Leukemia & Lymphoma, 32(1-2), 129-138.
- A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. Journal of Internal Medicine, 244(4), 271-292.
- Human myeloma cells shed the interleukin‐6 receptor: inhibition by tissue inhibitor of metalloproteinase‐3 and a hydroxamate‐based metalloproteinase inhibitor. British Journal of Haematology, 101(4), 694-702.
- Interleukin‐6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. British Journal of Haematology, 101(2), 287-295.
- Management of male osteoporosis: report of the UK Consensus Group. QJM, 91(2), 71-92.
- Immortalization of Human Marrow Stromal Cells by Retroviral Transduction With a Temperature Sensitive Oncogene: Identification of Bipotential Precursor Cells Capable of Directed Differentiation to Either an Osteoblast or Adipocyte Phenotype. Bone, 22(1), 7-16.
- Proteoglycan breakdown from bovine nasal cartilage is increased, and from articular cartilage is decreased, by extracellular ATP. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1362(2-3), 208-220.
- cDNA Cloning and Characterization of a Rat Spermatogenesis-Associated Protein RSP29. Biochemical and Biophysical Research Communications, 241(3), 714-719.
- Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity. British Journal of Haematology, 98(3), 665-672.
- Estrogen receptor mRNA in mineralized tissues of rainbow trout: calcium mobilization by estrogen. FEBS Letters, 411(1), 145-148. View this article in WRRO
- Effects of transforming growth factor beta on the production of prostaglandin E and caseinase activity of unstimulated and interleukin 1-stimulated human articular chondrocytes in culture.. Rheumatology, 36(7), 729-734.
- . Pharmaceutical Research, 14(5), 625-630.
- Expression of Members of a Novel Membrane Linked Metalloproteinase Family (ADAM) in Human Articular Chondrocytes. Biochemical and Biophysical Research Communications, 230(2), 335-339.
- Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. Biochemical Journal, 318(2), 459-462.
- Measurement of bone specific alkaline phosphatase in the horse: a comparison of two techniques. Research in Veterinary Science, 61(2), 160-164.
- Bisphosphonates Are Incorporated into Adenine Nucleotides by Human Aminoacyl-tRNA Synthetase Enzymes. Biochemical and Biophysical Research Communications, 224(3), 863-869.
- Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG-63) : regulation by interleukin-1 β and parathyroid hormone. Biochimica et Biophysica Acta (BBA) - General Subjects, 1290(1), 29-36.
- The Synthesis and Evaluation of Quaternary Pyridinium Bisphosphonates as Potent Anti-Resorptives. Phosphorus, Sulfur, and Silicon and the Related Elements, 111(1), 64-64.
- Chondrogenesis in the regenerating antler tip in red deer: Expression of collagen types I, IIA, IIB, and X demonstrated by in situ nucleic acid hybridization and immunocytochemistry. Developmental Dynamics, 205(3), 332-347.
- Effects of growth factors and interleukin-1 alpha on proteoglycan and type II collagen turnover in bovine nasal and articular chondrocyte pellet cultures.. Endocrinology, 137(8), 3557-3565.
- THE ANTI-RESORPTIVE DRUG CLODRONATE IS METABOLISED TO A NON-HYDROLYSABLE ATP ANALOGUE BY MAMMALIAN CELLS IN VITRO. Biochemical Society Transactions, 24(4), 562S-562S.
- The response of the skeleton to physical training: a biochemical study in horses. Bone, 17(3), 221-227.
- Age related changes in biochemical markers of bone metabolism in horses. Equine Veterinary Journal, 27(3), 201-207.
- Stimulation of cartilage resorption by extracellular ATP acting at P2-purinoceptors. Biochimica et Biophysica Acta (BBA) - General Subjects, 1201(2), 298-304.
- Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochemical Journal, 303(1), 303-311.
- The effect of interleukin-1β and transforming growth factor β on cathepsin B activity in human articular chondrocytes. Agents and Actions, 41(S2), C198-C200.
- Effects of transforming growth factor β and interleukin-1β on [3H]thymidine incorporation by human articular chondrocytes in vitro. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1226(2), 193-200.
- Diclofenac sodium inhibits bone resorption in postmenopausal women. The American Journal of Medicine, 96(4), 349-353.
- Biochemical measurements in Paget's disease of bone. Seminars in Arthritis and Rheumatism, 23(4), 240-241.
- Sulfasalazine may interfere with HPLC assay of urinary pyridinium crosslinks. Clinical Chemistry, 40(1), 167-168.
- Studies on type II collagen and aggrecan production in human articular chondrocytes in vitro and effects of transforming growth factor-β and interleukin-1β. Osteoarthritis and Cartilage, 2(4), 235-245.
- CELLS CULTURED FROM THE GROWING TIP OF RED DEER ANTLER EXPRESS ALKALINE PHOSPHATASE AND PROLIFERATE IN RESPONSE TO INSULIN-LIKE GROWTH FACTOR-I. Journal of Endocrinology, 143(2), R9-R16.
- Induction of Enhanced Responsiveness of Human Articular Chondrocytes to Extracellular ATP by Tumour Necrosis Factor-α. Clinical Science, 85(5), 569-575.
- Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis International, 3(5), 255-260.
- Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?. Bone and Mineral, 22(1), 1-8.
- Factors affecting the assay of urinary 3–hydroxy pyridiniurn crosslinks of collagen as markers of bone resorption. European Journal of Clinical Investigation, 23(6), 341-349.
- Cellular Regulatory Mechanisms that May Underlie the Effects of Corticosteroids on Bone. Rheumatology, 32(suppl 2), 6-10.
- Regulation of the phosphate (Pi) concentration in UMR 106 osteoblast-like cells: Effect of Pi, Na+ and K+. Cell Biochemistry and Function, 11(1), 13-23.
- The effect of age on bone collagen turnover as assessed by pyridinium crosslinks and procollagen I C-terminal peptide. Osteoporosis International, 3(S1), 100-101.
- Calciotropic hormones raise the chemically detectable [Pi] in UMR 106-06 osteoblast-like cells. Cell Biochemistry and Function, 11(1), 25-34.
- Metabolism of halogenated bisphosphonates by the cellular slime mould dictyostelium discoideum. Biochemical and Biophysical Research Communications, 189(1), 414-423.
- The effect of rat parathyroid hormone (1–34) infusion on urinary 3-hydroxypyridinium cross-link excretion in the rat. Bone and Mineral, 19(2), 117-125.
- Interleukin-1β enhances the response of human articular chondrocytes to extracellular ATP. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1137(1), 52-58.
- Spontaneous release of interleukin-1 and interleukin-6 by peripheral blood mononuclear cells after oophorectomy. Clinical Science, 83(4), 503-507.
- Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing. Clinical Science, 83(3), 375-382.
- Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clinical Endocrinology, 37(1), 45-50.
- Markers of bone and collagen breakdown in early inflammatory arthritis. Baillière's Clinical Rheumatology, 6(2), 351-372.
- Mechanisms of action of cyclosporine and effects on connective tissues. Seminars in Arthritis and Rheumatism, 21(6), 16-22.
- Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. Journal of Clinical Endocrinology & Metabolism, 74(3), 487-494.
- Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporosis International, 2(2), 94-102.
- Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis.. The Journal of Clinical Endocrinology & Metabolism, 74(3), 487-494.
- Parathyroid gland hormones in the skeletal development of the ovine foetus: the effect of parathyroidectomy with calcium and phosphate infusion. Bone and Mineral, 16(2), 121-129.
- Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1135(1), 97-102.
- Influx of phosphate (Pi) and methylglucose in MG-63 osteoblasts. Biochemical Society Transactions, 20(3), 278S-278S.
- The regulation of connective tissue metabolism by vasoactive intestinal polypeptide. Regulatory Peptides, 37(2), 111-121.
- Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. British Journal of Cancer, 66(6), 1159-1163.
- Cytokines: inflammatory mediators of joint disease. Equine Veterinary Journal, 24(2), 78-80.
- Cyclosporin A. Mode of Action and Effects on Bone and Joint Tissues. Scandinavian Journal of Rheumatology, 21(sup95), 9-18.
- Detection of mRNA for the transforming growth factor β family in human articular chondrocytes by the polymerase chain reaction. Biochemical and Biophysical Research Communications, 180(2), 602-608.
- The Modulation of the Expression of IL-6 and Its Receptor in Human Osteoblastsin Vitro*. Endocrinology, 129(3), 1513-1520.
- Evidence for the presence of P2-purinoceptors at the surface of human articular chondrocytes in monolayer culture. Biochimica et Biophysica Acta (BBA) - General Subjects, 1074(1), 151-158.
- OSTEOPOROSIS IN RHEUMATOID ARTHRITIS—THE LABORATORY PERSPECTIVE. Rheumatology, 30(2), 84-85.
- Hypophosphatasia and the Extracellular Metabolism of Inorganic Pyrophosphate: Clinical and Laboratory Aspects. Critical Reviews in Clinical Laboratory Sciences, 28(3), 195-232.
- 1,25-Dihydroxyvitamin D3 increases the Pi concentration in cultured osteoblasts. Biochemical Society Transactions, 18(4), 624-625.
- Constitutive and inducible expression of HLA class II determinants by human osteoblast-like cells in vitro.. Journal of Clinical Investigation, 85(5), 1421-1426.
- Independent induction of interleukin 6 and prostaglandin E2 by interleukin 1 in human articular chondrocytes. Biochemical and Biophysical Research Communications, 166(3), 1163-1170.
- Production of Tumor Necrosis Factor by Human Osteoblasts is Modulated by Other Cytokines, but not by Osteotropic Hormones*. Endocrinology, 126(2), 1250-1255.
- The effects of recombinant human interleukin-1β on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochemical and Biophysical Research Communications, 166(1), 208-216.
- P14. Circadian changes in bone turnover assessed by serum bone gla-protein and urinary deoxypyridinoline: effect of growth and ageing. Bone, 11(5), 380-380.
- Interactive regulation of signalling pathways in bone cells: Possible modulation of PGE2-stimulated adenylyl cyclase activity by protein kinase C. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1052(2), 323-326.
- Interleukin-1 stimulates diglyceride accumulation in the absence of protein kinase C activation. Regulatory Peptides, 29(2-3), 109-116.
- Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8. Cytokine, 2(2), 106-111.
- Calcium and orthophosphate deposits in vitro do not imply osteoblast-mediated mineralization: Mineralization by betaglycerophosphate in the absence of osteoblasts. Bone, 11(6), 385-391.
- Inhibition of interleukin-1-induced collagenase production in human articular chondrocytes in vitro by recombinant human interferon-gamma. Arthritis & Rheumatism, 33(11), 1733-1738.
- Parathyroid hormone raises the Pi concentration in a cultured osteoblast model. Biochemical Society Transactions, 18(5), 1010-1011.
- Selective extraction, concentration, and assay of orthophosphate from microliter quantities of cultured mammalian cells. Analytical Biochemistry, 181(1), 130-134.
- Modulation of human chondrocyte metabolism by recombinant human interferon gamma: in-vitro effects on basal and IL-1-stimulated proteinase production, cartilage degradation and DNA synthesis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1012(2), 128-134.
- The effects of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on human osteoblast-like cells. Biochemical and Biophysical Research Communications, 160(2), 588-595.
- Natural human IL-1β exhibits regulatory actions on human bone-derived cells invitro. Biochemical and Biophysical Research Communications, 159(3), 1242-1248.
- Agents affecting adenylate cyclase activity modulate the stimulatory action of 1,25-dihydroxyvitamin D3 on the production of osteocalcin by human bone cells. Biochemical and Biophysical Research Communications, 164(3), 1076-1085.
- Hypophosphatasia: Pediatric Forms. Journal of Pediatric Endocrinology and Metabolism, 3(2).
- Paget's disease of bone. Current Orthopaedics, 3(4), 262-269.
- 32P-labelling anomalies in human erythrocytes. Is there more than one pool of cellular Pi?. Biochemical Journal, 264(3), 729-736.
- An index to quantify the apparent regulation of orthophosphate concentration in mammalian cells. Biochemical Society Transactions, 17(1), 124-125.
- Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.. Journal of Clinical Investigation, 83(6), 1930-1935.
- The effect of tumor necrosis factor α and γ-interferon on the resorption of human articular cartilage and on the production of prostaglandin e and of caseinase activity by human articular chondrocytes. Arthritis & Rheumatism, 32(6), 780-784.
- Platelet-derived ATP may contribute to the measured concentration of inorganic pyrophosphate in serum.. Clinical Chemistry, 35(2), 326-326.
- Theoretical interpretation of isotope labelling experiments in cells in which the label is chemically incorporated: The example of orthophosphate. Journal of Theoretical Biology, 134(3), 351-364.
- Evidence that ecto-nucleoside-triphosphate pyrophosphatase serves in the generation of extracellular inorganic pyrophosphate in human bone and articular cartilage. Biochimica et Biophysica Acta (BBA) - General Subjects, 966(3), 310-317.
- Regulation of phosphate metabolism in human red cells following prolonged incubation to steady state in vitro. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 969(2), 139-147.
- Net fluxes of orthophosphate across the plasma membrane in human red cells following alteration of pH and extracellular Pi concentration. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 969(2), 148-157.
- Actions of recombinant human γ-interferon and tumor necrosis factor α on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro. Arthritis & Rheumatism, 31(12), 1500-1507.
- Contrasting effects of intravenous and oral etidronate on vitamin D metabolism in man. Clinical Science, 74(1), 101-106.
- Effects of the anabolic steroid stanozolol on cells derived from human bone. Clinical Science, 74(5), 455-460.
- Functional compartmentation of cellular orthophosphate in human erythrocytes revealed by 32Plabelling. Biochemical Society Transactions, 16(5), 781-782.
- Hypophosphatasia: biochemical screening of a Dutch kindred and evidence that urinary excretion of inorganic pyrophosphate is a marker for the disease.. Clinical Chemistry, 34(9), 1937-1941.
- The role of ecto-nucleoside triphosphate (NTP) pyrophosphatase in the pathogenesis of articular chondrocalcinosis. Biochemical Society Transactions, 15(6), 1090-1091.
- Anomalous 32P-labelling of human erythrocytes during prolonged incubations in vitro. Biochemical Society Transactions, 15(6), 1141-1142.
- Measurement of orthophosphate (Pi) concentration in suspensions of cultured mammalian cells. Biochemical Society Transactions, 15(6), 1140-1141.
- Orthophosphate (Pi) concentration in human erythrocytes after prolonged incubation to attain steady state in vitro. Biochemical Society Transactions, 15(5), 915-916.
- Effects of synthetic incubation media on phosphate metabolism in human erythrocytes. Biochemical Society Transactions, 15(5), 914-915.
- Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. Biochimica et Biophysica Acta (BBA) - General Subjects, 924(3), 473-482.
- Nucleoside triphosphate pyrophosphatase of rabbit matrix vesicles, a mechanism for the generation of inorganic pyrophosphate in epiphyseal cartilage. Biochimica et Biophysica Acta (BBA) - General Subjects, 924(2), 276-283.
- Factors Controlling the Intracellular Concentration of Orthophosphate (Pi) in Mammalian Cells, 469-478.
- CALCIUM IN MINERALIZED TISSUES AND PATHOLOGICAL CALCIFICATION. British Medical Bulletin, 42(4), 435-446.
- Homogeneous interferon-β-inducing 22K factor (IL-1β) has connective tissue cell stimulating activities. Biochemical and Biophysical Research Communications, 139(3), 1150-1157.
- Changes in plasma osteocalcin concentration following treatment with stanozolol. Clinica Chimica Acta, 158(1), 43-47.
- Effective short term treatment of Paget's disease with oral etidronate.. BMJ, 292(6513), 79-80.
- The Effect of Interleukin-l on Connective Tissue Metabolism and Its Relevance to Arthritis, 131-152.
- 1,25-Dihydroxyvitamin D3and Human Bone-Derived Cells in Vitro: Effects on Alkaline Phosphatase, Type I Collagen and Proliferation*. Endocrinology, 119(4), 1776-1785.
- A study of intracellular orthophosphate concentration in human muscle and erythrocytes by 31P nuclear magnetic resonance spectroscopy and selective chemical assay. Clinical Science, 71(6), 729-735.
- Cellular phosphate metabolism in patients receiving bisphosphonate therapy. Bone, 7(4), 255-259.
- Differential sensitivity to trypsin of human bone-derived cells in culture: Surface changes detected by partitioning in aqueous two-phase systems. Cell Biochemistry and Function, 4(1), 47-54.
- Metabolism of 25-hydroxycholecalciferol in a teleost fish, the rainbow trout (Salmo gairdneri). General and Comparative Endocrinology, 64(1), 143-150.
- Normal Activity of Nucleoside Triphosphate Pyrophosphatase in Alkaline Phosphatase-Deficient Fibroblasts from Patients with Infantile Hypophosphatasia*. The Journal of Clinical Endocrinology & Metabolism, 63(5), 1237-1241.
- Orthophosphate fluxes in human red cells in response to pH change. Biochemical Society Transactions, 14(6), 1193-1194.
- Parathyroid Hormone Stimulates the Proliferation of Cells Derived from Human Bone*. Endocrinology, 118(6), 2445-2449.
- Identification of ecto-nucleoside triphosphate pyrophosphatase in human articular chondrocytes in monolayer culture. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 847(1), 40-47.
- INTRAVENOUS CLODRONATE IN THE TREATMENT AND RETREATMENT OF PAGET'S DISEASE OF BONE. The Lancet, 325(8444), 1474-1477.
- Effects of dietary fish oil supplementation on the fatty acid composition of the human platelet membrane: demonstration of selectivity in the incorporation of eicosapentaenoic acid into membrane phospholipid pools. Clinical Science, 68(4), 449-454.
- Retinoids and synovial factor(s) stimulate the production of plasminogen activator by cultured human chondrocytes. A possible role for plasminogen activator in the resorption of cartilage in vitro. Biochimica et Biophysica Acta (BBA) - General Subjects, 838(1), 161-169.
- Partial purification of a factor from human synovium that possesses interleukin 1, chondrocyte stimulating and catabolin-like activities. FEBS Letters, 179(2), 247-251.
- Comparative effects of an antiviral drug, inosiplex, and diphosphonates in Paget's disease of bone. Bone, 6(2), 69-72.
- Mononuclear Cell Factor and Synovial Factor are Closely Related to, or Identical with, Interleukin-1. Rheumatology, XXIV(suppl 1), 55-58.
- The Effects of Mononuclear Cell Factor/Interleukin-1 on the Plasminogen Activators Produced by Human Chondrocytes. Rheumatology, XXIV(suppl 1), 118-121.
- A technique for the measurement of orthophosphate in human erythrocytes, and some studies of its determinants. Clinical Science, 69(4), 429-434.
- ABNORMAL VITAMIN D METABOLISM IN PAGET'S DISEASE OF BONE. Clinical Endocrinology, 22(4), 559-566.
- Modulation of connective tissue metabolism by partially purified human interleukin 1. Cellular Immunology, 90(1), 41-51.
- Phosphate metabolism in erythrocytes of critically ill patients. Clinical Science, 69(4), 435-440.
- Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity.. Journal of Clinical Investigation, 75(4), 1223-1229.
- Studies on the Actions of Interleukin-1 on Bone Metabolism: IL-1 Stimulation of Bone Cell Proliferation, and Inhibition of IL-1 Induced Bone Resorption by Interferon- . Rheumatology, XXIV(suppl 1), 147-149.
- The Effects of Mononuclear Cell Factor(MCF) and Interleukin-1 (IL-1) on Synthesis of Matrix by Skeletal and Articular Cells In Vitro. Rheumatology, XXIV(suppl 1), 158-161.
- Treatment of malignant hypercalcaemia with clodronate. British Journal of Cancer, 51(5), 665-669.
- Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human bone cells in vitro. Journal of Endocrinology, 105(3), 391-396.
- Enhanced production of prostaglandins and plasminogen activator during activation of human articular chondrocytes by products of mononuclear cells. Rheumatology International, 4(4), 143-149.
- Effects of bovine parathyroid hormone and 1,25-dihydroxyvitamin D3
on the production of prostaglandins by cells derived from human bone. FEBS Letters, 169(1), 49-52.
- In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis & Rheumatism, 27(6), 654-662.
- Stimulation by human interleukin 1 of cartilage breakdown and production of collagenase and proteoglycanase by human chondrocytes but not by human osteoblasts in vitro. Biochimica et Biophysica Acta (BBA) - General Subjects, 797(2), 186-193.
- Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metabolic Bone Disease and Related Research, 5(5), 229-234.
- Studies of the growth of human bone-derived cells in culture using aqueous two-phase partition. Bioscience Reports, 4(5), 415-419.
- The effects of monocyte-conditioned medium and interleukin 1 on the synthesis of collagenous and non-collagenous proteins by mouse bone and human bone cells in vitro. Biochimica et Biophysica Acta (BBA) - General Subjects, 801(1), 58-65.
- Effects of retinol and dexamethasone on cytokine-mediated control of metalloproteinases and their inhibitors by human articular chondrocytes and synovial cells in culture. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 763(2), 129-139.
- Urinary pyrophosphate excretion in renal stone formers with normal and impaired renal acidification. World Journal of Urology, 1(3), 150-154.
- EFFECTS OF INTRAVENOUS DIPHOSPHONATES ON RENAL FUNCTION. The Lancet, 321(8337), 1328-1328.
- An ultrastructural study of alkaline phosphatase in a transplantable rat osteogenic sarcoma. Metabolic Bone Disease and Related Research, 5(1), 23-31.
- Human Interleukin 1 Stimulates Bone Resorption in Vitro. Clinical Science, 64(2), 73P-73P.
- Drug treatment of primary hyperparathyroidism: use of clodronate disodium.. BMJ, 286(6365), 587-590.
- An interleukin 1 like factor stimulates bone resorption in vitro. Nature, 306(5941), 378-380.
- Effect of Aspirin on Urinary Excretion of 6-Ketoprostaglandin F1α. Clinical Science, 64(4), 395-398.
- THE USE OF DIPHOSPHONATES IN MYELOMA. British Journal of Haematology, 53(4), 688-690.
- The Presence in Normal Plasma, Serum and Platelets of Factors That Stimulate the Production of Prostacyclin (PGI2) by Cultured Endothelial Cells. Clinical Science, 64(4), 387-394.
- The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. British Journal of Haematology, 54(1), 121-132.
- Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals.. Annals of the Rheumatic Diseases, 42(Supplement 1), 27-37.
- Urinary 6-oxo prostaglandin F1 alpha in myocardial infarction.. BMJ, 287(6394), 727-727.
- Intracellular Inorganic Phosphate and ATP Levels in Human Blood Erythrocytes, Leucocytes and Platelets in Normal Subjects and in Diseases Associated with Altered Phosphate Metabolism, 147-155.
- Long-term treatment of osteoporosis with 24,25 dihydroxycholecalciferol. Acta Endocrinologica, 101(4), 636-640.
- Measurement of Intracellular Inorganic Phosphate in Human Blood Red Cells, Leucocytes and Platelets, 137-146.
- Properties of rheumatoid and normal synovial tissue in vitro and cells derived from them. Rheumatology International, 2(3), 113-120.
- Phosphoinositide metabolism in human blood platelets: Effects of two types of divalent cation chelators. Thrombosis Research, 26(4), 241-247.
- Adenylate cyclase of human articular chondrocytes. Responsiveness to prostaglandins and other hormones. Biochemical Journal, 208(1), 35-42.
- 1,25(Oh)2 D3 Binding Protein from Normal Pig Intestine: Characterisation and its Use in the Assay of Serum 1,25(Oh)2D3 Concentrations. Clinical Science, 62(2), 56P-57P.
- Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology.. Journal of Clinical Pathology, 35(7), 771-779.
- Enhanced Production of Prostaglandins by Synovial Cells in the Presence of Poly (I.C). Clinical Science, 62(2), 24P-24P.
- An Estimate of the Endogenous Secretion Rate of Calcitonin in Man. Clinical Science, 63(2), 145-152.
- Messenger function of prostaglandins in cell to cell interactions and control of proteinase activity in the rheumatoid joint. International Journal of Immunopharmacology, 4(2), 91-102.
- Characterization of Collagenase, other Metallo-Proteinases and An Inhibitor (Timp) Produced by Human Synovium and Cartilage in Culture. Clinical Science, 61(6), 711-716.
- Production of Collagenase and Inhibitor (Timp) by Normal, Rheumatoid and Osteoarthritic Synovium In Vitro: Effects of Hydrocortisone and Indomethacin. Clinical Science, 61(6), 703-710.
- Improved Assay For 6-Keto Prostaglandin F1α In Biological Fluids By Reversed-Phase High-Performance Liquid Chromatography In Conjunction With Radioimmunoassay. Oral Presentations.
- Strontium ions stimulate phosphoinositide metabolism in human blood platelets. FEBS Letters, 134(1), 88-90.
- Effects of Vitamin D Metabolites and Analogues on Renal Function. Nephron, 28(1), 17-25.
- Strontium ions induce production of thromboxane B2 and secretion of 5-hydroxytryptamine in washed human platelets. Biochemical Pharmacology, 30(6), 635-637.
- Effects of 24,25-dihydroxy-vitamin D3 on its plasma level in man. Metabolic Bone Disease and Related Research, 3(3), 155-158.
- Paget's disease: Improvment of spinal cord dysfunction with diphosphonates and Calcitonin. Metabolic Bone Disease and Related Research, 3(4-5), 327-335.
- Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis?. The Journal of Bone and Joint Surgery. British volume, 63-B(4), 495-503.
- IMPROVED SEPARATION OF PROSTAGLANDINS (PG'S) BY HPLC. Biochemical Society Transactions, 9(2), 225P-225P.
- Intercellular Messengers in Joint Tissues in Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 10(sup40), 75-87.
- Strontium Ions Stimulate The Metabolism Of Phosphoinositides In Human Blood Platelets. Oral Presentations.
- Biochemical markers of bone turnover in paget's disease. Metabolic Bone Disease and Related Research, 3(4-5), 255-262.
- Effects of corticosteroids on cellular interactions in human joint tissues in culture. Seminars in Arthritis and Rheumatism, 11(1), 138-139.
- Diphosphonates and paget's disease of bone. Metabolic Bone Disease and Related Research, 3(4-5), 217-217.
- Evidence for the involvement of microtubules in the ADP-induced secretion of platelet 14C-5-hydroxytryptamine. Thrombosis Research, 22(5-6), 525-533.
- Paget's bloom of bone : Diagnosis and management. Metabolic Bone Disease and Related Research, 3(4-5), 219-230.
- Stimulation of production of prostaglandin E in gingival cells exposed to products of human blood mononuclear cells. Biochemical Journal, 198(2), 391-396.
- The role of vitamin D metabolites in the osteomalacia of renal disease. Current Medical Research and Opinion, 7(5), 294-315.
- Human synovium releases a factor which stimulates chondrocyte production of PGE and plasminogen activator. Nature, 286(5776), 891-892.
- Lanthanum stimulates the accumulation of cyclic AMP and inhibits secretion and thromboxane B2 formation in human platelets. Biochimica et Biophysica Acta (BBA) - General Subjects, 632(2), 336-342.
- The Relationship between the Production of Thromboxane B2 and Malondialdehyde by Human Blood Platelets. Clinical Science, 59(2), 131-135.
2 production. Artery, 8(5), 487-493.
Studies on the role of calcium in the control of thromboxane B- OSTEOMALACIA IN RENAL DISEASE. The Lancet, 315(8166), 488-489.
- Biochemical and clinical responses to dichloromethylene diphosphonate (cl2mdp) in paget's disease of bone. Arthritis & Rheumatism, 23(10), 1185-1192.
- Response of Red Cell Phosphate to Acute and Chronic Changes in Plasma Phosphate in Man, 239-248.
- A factor from mononuclear cells stimulates prostaglandin E production by human gingival cells. Biochemical Society Transactions, 8(5), 527-528.
- Cell-cell interactions in the rheumatoid joint. Agents and Actions, 10(6), 486-490.
- Formation of calcium pyrophosphate crystals in vitro: implications for calcium pyrophosphate crystal deposition disease (pseudogout). Annals of the Rheumatic Diseases, 39(3), 222-227.
- Physiology and pharmacological regulation of bone resorption. Metabolic Bone Disease and Related Research, 2(3), 177-189.
- The effects of strontium and calcium ions on 5-hydroxytryptamine secretion and thromboxane B2 biosynthesis in washed human platelets. Biochemical Society Transactions, 8(5), 530-531.
- Radiometric measurement of pyrophosphate in cell cultures. Biochemical Society Transactions, 8(5), 529-530.
- The pathophysiology of hypercaemia. Metabolic Bone Disease and Related Research, 2(3), 151-159.
- The Interrelationship between Thromboxane Biosynthesis, Aggregation and 5-Hydroxytryptamine Secretion in Human Platelets in Vitro. Thrombosis and Haemostasis, 43(01), 038-040.
- Advances in metabolism. Nature, 280(5720), 343-343.
- Evidence that extracellular calcium ions inhibit thromboxane B2 biosynthesis by human platelets. Biochemical and Biophysical Research Communications, 90(4), 1179-1185.
- Effect of a Mononuclear-Cell Factor on Prostaglandin Production by Cells Cultured from Human Gingiva, Synovium, Cartilage and Endometrium. Biochemical Society Transactions, 7(5), 982-983.
- 24,25-Dihydroxycholecalciferol and calcium absorption in uraemia.. BMJ, 1(6166), 822-822.
- Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3′,5′-cyclic AMP and cyclic GMP in human platelets. Biochimica et Biophysica Acta (BBA) - General Subjects, 583(3), 344-351.
- The biological effects of 1, 24, 25-Trihydroxyvitamin D3 in man. Metabolic Bone Disease and Related Research, 1(4), 295-298.
- Loss of Metacarpal and Iliac Bone in Chronic Renal Failure: Influence of Haemodialysis, Parathyroid Activity, Type of Renal Disease, Physical Activity and Heparin Consumption. Clinical Science, 56(4), 317-324.
- Mode of action of dipyridamole on human platelets. Thrombosis Research, 16(3-4), 367-379.
- High affinity calcium binding peptides from the gills, gut and kidneys of the freshwater eel (Anguilla anguilla). Biochimica et Biophysica Acta (BBA) - Protein Structure, 536(2), 429-432.
- DIPYRIDAMOLE AND PLATELET FUNCTION. The Lancet, 312(8094), 846-846.
- The Absence of 24,25-Dihydroxycholecalciferol in Anephric Patients. Clinical Science, 55(6), 541-547.
- Formation Product of Calcium Pyrophosphate Crystals in Vitro and the Effect of Iron Salts. Clinical Science, 54(2), 29P-29P.
- Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature, 267(5614), 850-852.
- The Role of Inhibitors and other Factors in the Pathogenesis of Recurrent Calcium-Containing Renal Stones. Clinical Science, 53(2), 141-148.
- PROSTAGLANDINS AND BREAST CANCER. The Lancet, 310(8042), 829-829.
- Calcitonin's Role. New England Journal of Medicine, 297(7), 401-403.
- Changes in Histologic and Biochemical Indexes of Bone Turnover after Bilateral Nephrectomy in Patients on Hemodialysis. New England Journal of Medicine, 296(19), 1073-1079.
- Evidence for a Relationship between Plasma Immunoreactive Calcitonin and Bone Disease in chronic Renal Failure, 571-579.
- Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science, 195(4274), 181-183.
- CORRELATION OF CLINICAL, BIOCHEMICAL AND SKELETAL RESPONSES TO l α -HYDROXYVITAMIN D3IN RENAL BONE DISEASE. Clinical Endocrinology, 7(s1), 45s-50s.
- Biochemical measurements in Paget's disease of bone. European Journal of Clinical Investigation, 7(1), 37-39.
- PHYSIOLOGICAL AND THERAPEUTIC DIFFERENCES BETWEEN VITAMIN D, ITS METABOLITES AND ANALOGUES. Clinical Endocrinology, 7(s1), 191s-201s.
- FACTORS INFLUENCING THE RESPONSE TO lα-HYDROXYVITAMIN D3IN PATIENTS WITH RENAL BONE DISEASE. Clinical Endocrinology, 7(s1), 51s-57s.
- Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.. Archives of Disease in Childhood, 52(6), 473-481.
- EVIDENCE THAT ENDOGENOUS CALCITONIN PROTECTS AGAINST RENAL BONE DISEASE. The Lancet, 308(7999), 1322-1326.
- Cells cultured from human giant cell tumors of bone respond to parathyroid hormone. Calcified Tissue Research, 22(S1), 269-274.
- The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure. Calcified Tissue Research, 22(S1), 147-153.
- Histological measurements in Paget's disease of bone. Calcified Tissue Research, 22(S1), 295-297.
- Effect of Diphosphonates on Adenosine 3′:5′-Cyclic Monophosphate in Mouse Calvaria after Stimulation by Parathyroid Hormone in vitro. Clinical Science, 50(6), 473-478.
- Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment. The Journal of Bone and Joint Surgery. British volume, 58-B(1), 48-57.
- The Influence of Orthophosphate on the Renal Handling of Inorganic Pyrophosphate in Man and Dog. Clinical Science, 51(5), 435-443.
- The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochimica et Biophysica Acta (BBA) - Enzymology, 429(2), 429-438.
- Metabolism of inorganic pyrophosphate (PPi). Arthritis & Rheumatism, 19(S3), 465-478.
- Regulation of Calcium Metabolism. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 13(1-6), 518-539.
- Effects of a diphosphonate (disodium etidronate; EHDP) on phosphate metabolism in Paget’s disease of bone, primary hyperparathyroidism and type I hypophosphataemic rickets. Calcified Tissue Research, 21(1), 339-343.
- The comparative effects of vitamin D deficiency and ethane-1-hydroxy-1,1-diphosphonate administration on the histology and glycolysis of chick epiphyseal and articular cartilage. Calcified Tissue Research, 19(1), 139-152.
- Changes in the Renal and Extrarenal Handling of Phosphate Induced by Disodium Etidronate (EHDP) in Man. Clinical Science, 49(1), 45-56.
- Pyrophosphate and Diphosphonates in Skeletal Metabolism. Clinical Orthopaedics and Related Research, 108, 241-263.
- The Effect of 1,25-Dihydroxycholecalciferol on Renal Tubular Reabsorption of Phosphate, Intestinal Absorption of Calcium and Bone Histology in Hypophosphataemic Renal Tubular Rickets. Clinical Science, 48(3), 177-186.
- An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in paget's disease. Clinica Chimica Acta, 63(2), 227-229.
- 1,25-DIHYDROXYCHOLECALCIFEROL AND 1α-HYDROXYCHOLECALCIFEROL IN HYPOPARATHYROIDISM. The Lancet, 304(7871), 14-17.
- DIPHOSPHONATES IN PAGET'S DISEASE. The Lancet, 303(7863), 894-898.
- EFFECTS OF 1,25-DIHYDROXYCHOLECALCIFEROL ON CALCIUM ABSORPTION, MUSCLE WEAKNESS, AND BONE DISEASE IN CHRONIC RENAL FAILURE. The Lancet, 303(7854), 379-384.
- Some Long-Term Effects of 1,25 Dihydroxycholecalciferol (1,25(OH)2D3) in Man. Clinical Science, 46(2), 10P-10P.
- Some Effects of Disodium Ethane-1-Hydroxy-1,1-Diphosphonate (EHDP) on Calcium Metabolism in Man. Clinical Science, 47(3), 13P-14P.
- Influence of dichloromethylene diphosphonate (Cl2MDP) and calcitonin on bone resorption, lactate production and phosphatase and pyrophosphatase content of mouse calvaria treated with parathyroid hormonein vitro. Calcified Tissue Research, 13(1), 287-294.
- Calcitonin in osteogenesis imperfecta.. BMJ, 2(5858), 114-114.
- Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone. Calcified Tissue Research, 11(3), 179-195.
- Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcified Tissue Research, 11(3), 196-214.
- DIPHOSPHONATES. The Journal of Bone and Joint Surgery. British volume, 55-B(1), 66-86.
- Relationship between pyrophosphate, amorphous calcium phosphate and other factors in the sequence of calcificationin vivo. Calcified Tissue Research, 10(1), 198-206.
- Relation between Alkaline Phosphatase and Ca2+-ATPase in Calcium Transport. Nature New Biology, 240(99), 126-127.
- The Influence of Disodium Ethane-1-Hydroxy-1,1-Diphosphonate (Ehdp) on the Development of Experimentally Induced Urinary Stones in Rats. Clinical Science, 42(2), 197-207.
- TREATMENT OF MYOSITIS OSSIFICANS PROGRESSIVA WITH A DIPHOSPHONATE. The Lancet, 299(7740), 10-12.
- A Review of the Physiological and Pharmacological Effects of Pyrophosphate and Diphosphonates on Bones and Teeth. Journal of Dental Research, 51(2), 323-332.
- DIPHOSPHONATES AND PAGET'S DISEASE OF BONE. The Lancet, 297(7706), 945-947.
- Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. Journal of Clinical Investigation, 50(5), 961-969.
- The Effects of Diphosphonates, Polyphosphates, and Calcitonin on "Immobilisation Osteoporosis" in Rats. European Journal of Clinical Investigation, 1(5), 336-344.
- The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatitein vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcified Tissue Research, 6(1), 183-196.
- INORGANIC PYROPHOSPHATE IN PLASMA, URINE, AND SYNOVIAL FLUID OF PATIENTS WITH PYROPHOSPHATE ARTHROPATHY (CHONDROCALCINOSIS OR PSEUDOGOUT). The Lancet, 296(7679), 899-902.
- 7 Inorganic Pyrophosphate and Pyrophosphatases in Calcification and Calcium Homeostasis. Clinical Orthopaedics and Related Research, 69(1), 101???117-101???117.
- The concentration of inorganic pyrophosphate in human saliva and dental calculus. Archives of Oral Biology, 15(12), 1389-1392.
- The Inhibitory Effect of Phosphonates on the Formation of Calcium Phosphate Crystals in vitro and on Aortic and Kidney Calcification in vivo. European Journal of Clinical Investigation, 1(1), 12-18.
- The Regulation of Calcium Metabolism [Abridged]. Proceedings of the Royal Society of Medicine, 63(9), 876-876.
- Prevention by a Diphosphonate of Immobilization “Osteoporosis” in Rats. Nature, 223(5202), 211-212.
- Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivo. Science, 165(3899), 1264-1266.
- Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo. Science, 165(3899), 1262-1264.
- Pyrophosphate and Diphosphonates in Calcium Metabolism and Their Possible Role in Renal Failure. Archives of Internal Medicine, 124(5), 571-571.
- Influence of pyrophosphate on the transformation of amorphous to crystalline calcium phosphate. Calcified Tissue Research, 2(1), 49-59.
- The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcified Tissue Research, 2(S1), 10-10.
- Stimulation of phosphate excretion by the renal arterial infusion of 3′5′-AMP (cyclic AMP)—A possible mechanism of action of parathyroid hormone. Calcified Tissue Research, 2(S1), 54-54.
- Phosphorus Depletion in Man. New England Journal of Medicine, 279(2), 109-109.
- Isolation of inorganic pyrophosphate from bovine and human teeth. Archives of Oral Biology, 13(6), 683-696.
- STUDY OF BURN TOXINS. Annals of the New York Academy of Sciences, 150(3 Early Treatme), 807-815.
- Influence of Pyrophosphate on the Crystallisation of Uric Acid and Magnesium Ammonium Phosphate and its Implications in Phosphate Therapy for Urolithiasis. Urologia Internationalis, 22(6), 483-491.
- Effect of Pyrophosphate on Hydroxyapatite and Its Implications in Calcium Homeostasis. Nature, 212(5065), 901-903.
- Effect of Pyrophosphate on Dissolution of Hydroxyapatite and Its Possible Importance in Calcium Homeostasis.. Experimental Biology and Medicine, 122(2), 317-320.
- EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA. The Lancet, 286(7410), 461-464.
- THE EFFECT OF ORAL PHOSPHATE IN PATIENTS WITH RECURRENT RENAL CALCULUS. British Journal of Urology, 37(4), 390-398.
- The Activating Effect of Lead on the Precipitation of Calcium Phosphate.. Experimental Biology and Medicine, 118(4), 882-884.
- URINARY PYROPHOSPHATE AND UROLITHIASIS. The Lancet, 283(7348), 1446-1446.
- The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-[gamma] mice. Bone Abstracts.
- Eliminating the need for fasting with oral administration of bisphosphonates. Therapeutics and Clinical Risk Management, 395-395.
- Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Therapeutics and Clinical Risk Management, 325-325.
- Novel Mutations in ACVR1 Result in Atypical Features in Two Fibrodysplasia Ossificans Progressiva Patients. PLoS ONE, 4(3), e5005-e5005.
- Osteonecrosis of the Jaw: More Heat Than Light. Journal of Nuclear Medicine, 50(1), 6-7.
- Bim, Bak, and Bax Regulate Osteoblast Survival. Journal of Bone and Mineral Research, 23(5), 610-620.
- Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 6(12), 3219-3228.
- Herbert Andre Fleisch, MD. Journal of Bone and Mineral Research, 22(11), 1651-1653.
- Nitrogen-Containing Biphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras. Journal of Bone and Mineral Research, 20(7), 1265-1274.
- Clinical Disorders of Bone Resorption, 251-271.
- Heterocycle-Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure-Activity Relationships in J774 Macrophages. Journal of Bone and Mineral Research, 13(11), 1668-1678.
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras. Journal of Bone and Mineral Research, 13(4), 581-589.
- Expression of Type X Collagen and Matrix Calcification in Three-Dimensional Cultures of Immortalized Temperature-Sensitive Chondrocytes Derived from Adult Human Articular Cartilage. Journal of Bone and Mineral Research, 13(3), 432-442.
- Clodronate and Liposome-Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5′-(β,γ-Dichloromethylene) Triphosphate, by Mammalian Cells In Vitro. Journal of Bone and Mineral Research, 12(9), 1358-1367.
- Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. Journal of Bone and Mineral Research, 11(10), 1482-1491.
- Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictyostelium discoideum. Journal of Bone and Mineral Research, 9(7), 1029-1039.
- Modulation of ecto-nucleoside triphosphate pyrophosphatase activity of human osteoblast-like bone cells by 1α,25-dihydroxyvitamin D3, 24R, 25-dihydroxyvitamin D3, parathyroid hormone, and dexamethasone. Journal of Bone and Mineral Research, 9(8), 1259-1266.
- Transforming growth factor β increases ecto-nucleoside triphosphate pyrophosphatase activity of human bone-derived cells. Journal of Bone and Mineral Research, 9(1), 99-109.
- The effect of transforming growth factor β on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63. Journal of Bone and Mineral Research, 7(12), 1363-1371.
- Human osteoblastlike cells do not respond to interleukin-6. Journal of Bone and Mineral Research, 6(2), 141-148.
- Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. Journal of Bone and Mineral Research, 6(1), 3-8.
- Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. Journal of Bone and Mineral Research, 5(9), 983-988.
- Duration of Effect of Oral Diphosphonate Therapy in Paget's Disease of Bone. QJM: An International Journal of Medicine.
- An Evaluation of 1a-Hydroxy-and 1,25-Dihydroxyvitamin D3 in the Treatment of Renal Bone Disease, 12-28.
- Possible Function of Different Renal Metabolites of Vitamin D in Man, 192-211.
- Treatment of Renal Bone Disease with 1α-Hydroxylated Derivatives of Vitamin D3
CLINICAL, BIOCHEMICAL, RADIOGRAPHIC AND HISTOLOGICAL RESPONSES . QJM: An International Journal of Medicine. - Frequencies of HLA-A and HLA-B Histocompatibility Antigens in Paget's Disease of Bone. Tissue Antigens, 7(1), 55-56.
- Paget's Disease of Bone
EXPERIENCE WITH A DIPHOSPHONATE (Disodium etidronate) IN TREATMENT . QJM: An International Journal of Medicine.
Chapters
- Clinical and translational pharmacology of bisphosphonates, Principles of Bone Biology (pp. 1671-1687). Elsevier
- Antiresorptives, The Duration and Safety of Osteoporosis Treatment (pp. 17-36). Springer International Publishing
- Bisphosphonates, Osteogenesis Imperfecta (pp. 495-500). Elsevier
- Bisphosphonates, Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease (pp. 495-500).
- Bisphosphonates, Principles of Bone Biology (pp. 1737-1767). Elsevier
- Recommendations for Performing Bone Densitometry to Diagnose Osteoporosis and Identify Persons to Be Treated for Osteoporosis, Osteoporosis and the Osteoporosis of Rheumatic Diseases (pp. 27-32). Elsevier
- Growth Factors, Dynamics of Bone and Cartilage Metabolism (pp. 99-113). Elsevier
- Immune Cells and Bone Resorption, Phosphate and Mineral Homeostasis (pp. 261-273). Springer US
- Physiological and Pharmacological Aspects of 24,25-Dihydroxycholecalciferol in Man, Homeostasis of Phosphate and Other Minerals (pp. 487-503). Springer US
Conference proceedings papers
- P290 Real-time impedance-based monitoring of the growth and inhibition of osteomyelitis pathogen Staphylococcus aureus biofilms treated with novel bisphosphonate-fluoroquinolone antimicrobial conjugates. Bone Reports, Vol. 13(Supplement) (pp 83-84). Online, 22 October 2020 - 24 October 2020.
- The Ability of Bisphosphonates and Their Analogues to Penetrate the Osteocyte Network is Dependent on Affinity for Bone. Bone, Vol. 46 (pp S22-S22)
- Fluorescently labeled risedronate and related analogs: Design and evaluation as imaging probes. Bone, Vol. 42 (pp S36-S36)
- A mirror image pair of bisphosphonate analogs further demonstrates the mode of binding of the bisphosphonates in farnesyl pyrophosphate synthase. Bone, Vol. 42 (pp S36-S37)
- Evaluation of the relative mineral-binding affinities of clinically-relevant bisphosphonates by using hydroxyapatite-column chromatography and adsorption isotherms combined with mass spectrometric analysis. Bone, Vol. 42 (pp S90-S91)
- Bisphosphonates: The evolution of a gold standard. Bone, Vol. 41(5) (pp S29-S29)
- Bisphosphonates: Mode of Action and Pharmacology. Pediatrics, Vol. 119(Supplement 2) (pp S150-S162)
- Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy. Annals of the New York Academy of Sciences, Vol. 1117(1) (pp 209-257)
- Bone biology and the pathogenesis of osteoporosis. Current Opinion in Rheumatology, Vol. 18(Suppl 1) (pp S3-S10)
- Bisphosphonates: From Bench to Bedside. Annals of the New York Academy of Sciences, Vol. 1068(1) (pp 367-401)
- Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. Journal of Organometallic Chemistry, Vol. 690(10) (pp 2679-2687)
- Osteoporosis: pathogenesis and clinical intervention. Biochemical Society Transactions, Vol. 31(2) (pp 462-464)
- Overview of bisphosphonates. Cancer, Vol. 80(S8) (pp 1652-1660)
- The Assessment of Bone MetabolismIn VivoUsing Biochemical Approaches. Hormone and Metabolic Research, Vol. 29(03) (pp 138-144)
- Extracellular ATP stimulates resorption of bovine nasal cartilage. Biochemical Society Transactions, Vol. 18(5) (pp 951-952)
Patents
- Growth Factors. Appl. 01 Dec 2006.
Preprints
- In vitroandin vivoeffects of zoledronate on senescence and senescence-associated secretory phenotype markers, Cold Spring Harbor Laboratory.
- Foreword I. Elsevier.